XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
B
B

Biomarin

뉴스

Reuters - 1 주 전

U.S. STOCKS IDEXX, Amgen, Airbnb

BUZZ-U.S. STOCKS ON THE MOVE-IDEXX, Amgen, Airbnb Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
I
U
U
F
M
R
U
V
M
Reuters - 1 주 전

U.S. STOCKS Lumen Technologies, Broadridge Financial, IDEXX

BUZZ-U.S. STOCKS ON THE MOVE-Lumen Technologies, Broadridge Financial, IDEXX Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
C
I
U
U
F
M
R
T
U
B
J
M
Reuters - 1 주 전

BioMarin up as investors applaud new focus for hemophilia gene therapy

BUZZ-BioMarin up as investors applaud new focus for hemophilia gene therapy ** Shares of BioMarin Pharmaceutical BMRN.O rise ~8% to hit over 3-month high of $86.48 ** BMRN plans to cut direct annual expenses for its hemophilia gene therapy, Roctavian , by directing commercial focus to markets in the U.S., Germany and Italy ** Co anticipates reducing annual direct expenses on Roctavian to ~$60 million beginning in 2025 ** "Investors appear to be applauding the decision to downsize Roctavian's exp
B
Reuters - 1 주 전

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T
Reuters - 1 주 전

U.S. Actinium, Albemarle, ArcBest

U.S. RESEARCH ROUNDUP- Actinium, Albemarle, ArcBest Aug 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Actinium Pharmaceuticals, Albemarle and ArcBest, on Tuesday. HIGHLIGHTS * Actinium Pharmaceuticals Inc ATNM.A : JonesTrading cuts PT to $9 from $26 * Albemarle ALB.N : Baird cuts to neutral; cuts target price to $85 from $102 * ArcBest Corp ARCB.O : Stephens cuts target price to $130 from $145 * Crispr Therapeuti
A
A
B
B
C
C
C
C
D
Reuters - 1 주 전

Biomarin Pharmaceutical Inc reports results for the quarter ended in June - Earnings Summary

Biomarin Pharmaceutical Inc reports results for the quarter ended in June - Earnings Summary Biomarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 56 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 29 cents. The mean expectation of twenty five analysts for the quarter was for earnings of 35 cents per share.
B
Reuters - 1 주 전

BioMarin climbs after Q2 results beat

BUZZ-BioMarin climbs after Q2 results beat ** Shares of therapy developer BioMarin BMRN.O rise ~5.6% to $84.99 in after-hours trading ** BMRN reports Q2 adj. profit of 96 cents/shr vs analysts' average estimate of 35 cents/shr - LSEG data ** Company's quarterly revenue of $712 mln also beats analysts' expectation of $662.1 mln ** BMRN forecasts annual adj.
B
Reuters - 1 주 전

Biomarin Pharmaceutical Q2 EPS USD 0.55

BRIEF-Biomarin Pharmaceutical Q2 EPS USD 0.55 Aug 05 (Reuters) - Biomarin Pharmaceutical Q2 revenue USD 712 million vs. IBES estimate USD 662.1 million. Q2 basic EPS USD 0.56 Q2 adjusted EPS USD 0.96 vs. IBES estimate USD 0.35 Q2 net income USD 107.2 million vs. IBES estimate USD 70.5 million
B
Reuters - 3 주 전

US FDA Approves Biomarin's Brineura For Children Under 3 Years With CLN2 Disease

BRIEF-US FDA Approves Biomarin's Brineura For Children Under 3 Years With CLN2 Disease July 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : U.S. FOOD AND DRUG ADMINISTRATION APPROVES BIOMARIN'S BRINEURA® (CERLIPONASE ALFA) FOR CHILDREN UNDER 3 YEARS WITH CLN2 DISEASE Source text for Eikon: ID:nPn4g5vV5a Further company coverage: BMRN.O
B
Reuters - 3 주 전

Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial

UPDATE 1-Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial Adds background on data and disorder throughout July 24 (Reuters) - Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.
B
P
Reuters - 2 달 전

BridgeBio climbs on positive mid-stage trial for genetic condition treatment

BUZZ-BridgeBio climbs on positive mid-stage trial for genetic condition treatment ** Shares of drug developer BridgeBio Pharma BBIO.O rise ~8% to $31.29 premarket ** Co says its oral therapy infigratinib showed significant improvement in body proportionality in patients with achondroplasia, during a mid-stage trial ** Achondroplasia is a genetic bo
B
Reuters - 3 달 전

U.S. Bath & Body Works, Under Armour, Viking Therapeutics

U.S. RESEARCH ROUNDUP-Bath & Body Works, Under Armour, Viking Therapeutics May 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Bath & Body Works, Under Armour and Viking Therapeutics, on Friday. HIGHLIGHTS * Advanced Drainage Systems Inc WMS.N : Barclays raises target price to $202 from $189 * Bath & Body Works Inc BBWI.N : JP Morgan raises to neutral from underweight * Tanger Inc SKT.N : Scotiabank raises to sect
B
C
G
M
T
A
A
C
D
T
Reuters - 3 달 전

Third Point Llc Takes Share Stake In Alphabet, Advance Auto Parts; Dissolves In U.S. Steel, Dupont

BRIEF-Third Point Llc Takes Share Stake In Alphabet, Advance Auto Parts; Dissolves In U.S. Steel, Dupont May 15 (Reuters) - Third Point LLC: THIRD POINT LLC TAKES SHARE STAKE OF 3.0 MILLION SHARES OF CLASS A CAPITAL STOCK - SEC FILING THIRD POINT LLC TAKES SHARE STAKE OF 1.5 MILLION SHARES IN ADVANCE AUTO PARTS INC THIRD POINT LLC DISSOLVES SHARE S
B
G
U
M
A

조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.